Unknown

Dataset Information

0

Kobophenol A Inhibits Binding of Host ACE2 Receptor with Spike RBD Domain of SARS-CoV-2, a Lead Compound for Blocking COVID-19.


ABSTRACT: In the search for inhibitors of COVID-19, we have targeted the interaction between the human angiotensin-converting enzyme 2 (ACE2) receptor and the spike receptor binding domain (S1-RBD) of SARS-CoV-2. Virtual screening of a library of natural compounds identified Kobophenol A as a potential inhibitor. Kobophenol A was then found to block the interaction between the ACE2 receptor and S1-RBD in vitro with an IC50 of 1.81 ± 0.04 ?M and inhibit SARS-CoV-2 viral infection in cells with an EC50 of 71.6 ?M. Blind docking calculations identified two potential binding sites, and molecular dynamics simulations predicted binding free energies of -19.0 ± 4.3 and -24.9 ± 6.9 kcal/mol for Kobophenol A to the spike/ACE2 interface and the ACE2 hydrophobic pocket, respectively. In summary, Kobophenol A, identified through docking studies, is the first compound that inhibits SARS-CoV-2 binding to cells through blocking S1-RBD to the host ACE2 receptor and thus may serve as a good lead compound against COVID-19.

SUBMITTER: Gangadevi S 

PROVIDER: S-EPMC7901140 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Kobophenol A Inhibits Binding of Host ACE2 Receptor with Spike RBD Domain of SARS-CoV-2, a Lead Compound for Blocking COVID-19.

Gangadevi Suresh S   Badavath Vishnu Nayak VN   Thakur Abhishek A   Yin Na N   De Jonghe Steven S   Acevedo Orlando O   Jochmans Dirk D   Leyssen Pieter P   Wang Ke K   Neyts Johan J   Yujie Tao T   Blum Galia G  

The journal of physical chemistry letters 20210212 7


In the search for inhibitors of COVID-19, we have targeted the interaction between the human angiotensin-converting enzyme 2 (ACE2) receptor and the spike receptor binding domain (S1-RBD) of SARS-CoV-2. Virtual screening of a library of natural compounds identified Kobophenol A as a potential inhibitor. Kobophenol A was then found to block the interaction between the ACE2 receptor and S1-RBD <i>in vitro</i> with an IC<sub>50</sub> of 1.81 ± 0.04 μM and inhibit SARS-CoV-2 viral infection in cells  ...[more]

Similar Datasets

| S-EPMC8395245 | biostudies-literature
| S-EPMC9851952 | biostudies-literature
| S-EPMC7832953 | biostudies-literature
| S-EPMC8673933 | biostudies-literature
| S-EPMC7876913 | biostudies-literature
| S-EPMC9786537 | biostudies-literature
| EMPIAR-10951 | biostudies-other
| EMPIAR-10952 | biostudies-other
| S-EPMC9353385 | biostudies-literature